Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Phase 3

Terminated

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: bortezomib
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2007-08-29

Last Posted Date: 2015-06-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00522392

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Northbay Cancer Center, Fairfield, California, United States
🇺🇸
Kaiser Permanente, San Diego, California, United States

and more 273 locations

PRelationship Between Physical Activity and Cancer Ris

Completed

Conditions: Cancer

First Posted Date: 2007-08-28

Last Posted Date: 2020-09-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 620

Registration Number: NCT00521651

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇨🇳
Shanghai National Cancer Institute, Shanghai, China

Metabolism and Thyroid Hormone Changes During Exposure to Cold Temperatures

Not Applicable

Completed

Conditions: Obesity

First Posted Date: 2007-08-28

Last Posted Date: 2019-12-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 160

Registration Number: NCT00521729

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Phase 2

Withdrawn

Conditions: AIDS-related Kaposi Sarcoma
Classic Kaposi Sarcoma

Interventions: Drug: sunitinib malate
Procedure: laboratory biomarker analysis
Procedure: pharmacological study

First Posted Date: 2007-08-27

Last Posted Date: 2014-05-05

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00521092

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3

Terminated

Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer
Breast Carcinoma

Interventions: Drug: Carboplatin
Biological: Bevacizumab
Drug: Paclitaxel
Other: Placebo
Biological: Trastuzumab

First Posted Date: 2007-08-27

Last Posted Date: 2025-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00520975

Locations: 🇺🇸
NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States
🇺🇸
East Bay Radiation Oncology Center, Castro Valley, California, United States
🇺🇸
Eden Hospital Medical Center, Castro Valley, California, United States

and more 370 locations

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Small Cell Lung Cancer

Interventions: Drug: obatoclax mesylate
Drug: topotecan hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2007-08-27

Last Posted Date: 2015-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00521144

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Hodgkin's Lymphoma
Non-Hodgkin's Disease
Acute Leukemia
Multiple Myeloma

Interventions: Biological: Rituximab
Drug: Allogenic stem cell transplant (ASCT)
Drug: Cyclosporine
Drug: Conditioning Chemotherapy
Drug: TMS
Drug: FLAG
Drug: EPOCH-F
Biological: Alemtuzumab

First Posted Date: 2007-08-23

Last Posted Date: 2019-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00520130

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Phase 2

Completed

Conditions: Ewing Sarcoma of Bone
Extraosseous Ewing Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Peripheral Primitive Neuroectodermal Tumor

Interventions: Drug: topotecan hydrochloride
Drug: vincristine sulfate
Drug: cyclophosphamide
Biological: bevacizumab

First Posted Date: 2007-08-15

Last Posted Date: 2014-09-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00516295

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer

Phase 1

Completed

Conditions: Progesterone Receptor-negative Breast Cancer
Stage I Breast Cancer
Stage IIIB Breast Cancer
Estrogen Receptor-negative Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer

Interventions: Other: placebo
Other: quality-of-life assessment
Procedure: questionnaire administration
Drug: defined green tea catechin extract
Procedure: laboratory biomarker analysis

First Posted Date: 2007-08-15

Last Posted Date: 2014-09-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00516243

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 1 locations

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma

Interventions: Drug: sunitinib malate

First Posted Date: 2007-08-09

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT00514137

Locations: 🇺🇸
Mayo Clinic Cancer Research Consortium, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy